Cardiac POC Testing Devices - Global Strategic Business Report

The global market for Cardiac POC Testing Devices was estimated at US$1.6 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing at a CAGR of 5.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Cardiac POC Testing Devices market.

Global Cardiac POC Testing Devices Market - Key Trends and Drivers Summarized

Cardiac Point-of-Care (POC) testing devices are medical tools designed to provide immediate and accurate diagnostic results at or near the site of patient care. These devices are crucial in the rapid diagnosis and management of cardiovascular conditions, including heart attacks, heart failure, and other cardiac-related emergencies. Cardiac POC testing devices typically include handheld devices, portable analyzers, and compact lab-in-a-box systems that measure biomarkers such as troponin, BNP (B-type natriuretic peptide), and D-dimer from a small blood sample. The primary advantage of these devices lies in their ability to deliver quick results, often within minutes, thereby facilitating prompt clinical decision-making and improving patient outcomes.

The deployment of cardiac POC testing devices has revolutionized the approach to diagnosing and managing cardiac conditions. Traditionally, diagnosing heart-related issues required sending samples to centralized laboratories, resulting in longer turnaround times. Cardiac POC testing devices mitigate this delay by providing on-the-spot results, which is critical in emergency settings where time is of the essence. Hospitals, emergency departments, ambulances, and even remote clinics have increasingly adopted these devices to enhance their diagnostic capabilities. Furthermore, advancements in sensor technology and microfluidics have significantly improved the accuracy and reliability of cardiac POC testing, making them a valuable tool for healthcare professionals.

The growth in the cardiac POC testing devices market is driven by several factors. The increasing prevalence of cardiovascular diseases, coupled with the growing demand for rapid and accurate diagnostic tools, is a primary driver of market expansion. Technological advancements, including the miniaturization of devices and the integration of digital health solutions, have made these devices more accessible and user-friendly, boosting their adoption across various healthcare settings. The shift towards decentralized healthcare, emphasizing point-of-care diagnostics to reduce the burden on centralized labs and hospitals, also contributes to market growth. Additionally, the rising awareness about the importance of early diagnosis and the management of cardiac conditions among patients and healthcare providers further propels the demand for these devices. Regulatory support and favorable reimbursement policies in many regions enhance market penetration and accessibility.

SCOPE OF STUDY:

The report analyzes the Cardiac POC Testing Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

• Segments: Segment (Cardiac Markers Test, Analyzers); End-Use (Hospitals & Laboratories, Diagnostic Centers, Other End-Uses)
• Geographic Regions/Countries: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Cardiac Markers Test segment, which is expected to reach US$1.6 Billion by 2030 with a CAGR of a 5.8%. The Analyzers segment is also set to grow at 5.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $582.9 Million in 2024, and China, forecasted to grow at an impressive 6.9% CAGR to reach $258.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Cardiac POC Testing Devices Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cardiac POC Testing Devices Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Cardiac POC Testing Devices Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Inc., Danaher Corporation, HemoCue AB, Alfa Scientific Designs, Inc., BG Medicine, Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 50 companies featured in this Cardiac POC Testing Devices market report include:

• Abbott Laboratories, Inc.
• Danaher Corporation
• HemoCue AB
• Alfa Scientific Designs, Inc.
• BG Medicine, Inc.
• Boditech Med, Inc.
• Jant Pharmacal Corporation
• Creative Diagnostics
• AccuBioTech Co., Ltd.
• BIOBASE
• DiaSys Diagnostics India Pvt., Ltd.
• Biosynex SA
• Humasis Co Ltd
• Diagnoptics
• CTK Biotech, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.